Human cardiac stem cells rejuvenated by modulating autophagy with MHY-1685 enhance the therapeutic potential for cardiac repair
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCISCIEScopus
- 저널 순위
- JCR Q1Scopus Q1KCI Q4
- 저널
- Experimental and Molecular Medicine53(9) · pp.1423 · 2021
- 피인용
- Web of Science 13Scopus 12KCI 1
- FWCI (Scopus)
- 0.64
- JCR IF
- JCR 2020 8.718
- ISSN
- 1226-3613
저자
- 박지혜제1저자Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- Kim, HyeokCatholic Univ Korea, Coll Med, Dept Med Life Sci, 222 Banpo Daero, Seoul 137701, South Korea
- 문형룡Pusan Natl Univ, Coll Pharm, Lab Med Chem, Busan 46241, South Korea
- Park, Bong-WooCatholic Univ Korea, Coll Med, Dept Med Life Sci, 222 Banpo Daero, Seoul 137701, South Korea
- Park, Jae-HyunCatholic Univ Korea, Coll Med, Dept Med Life Sci, 222 Banpo Daero, Seoul 137701, South Korea
- Sim, Woo-SupCatholic Univ Korea, Coll Med, Dept Med Life Sci, 222 Banpo Daero, Seoul 137701, South Korea
- Kim, Jin-JuCatholic Univ Korea, Coll Med, Dept Med Life Sci, 222 Banpo Daero, Seoul 137701, South Korea
- 임혜지Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 김연주Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 지승택Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 장웅비Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 비노스 쿠마르 레티네스와란Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 레 티 홍 반Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 리 탄 쯔엉 강Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 윤지수Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- 하종성Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
- Ban, KiwonCity Univ Hong Kong, Dept Biomed Sci, Kowloon, Tat Chee Ave, Hong Kong, Peoples R China
- 정해영Pusan Natl Univ, Coll Pharm, Mol Inflammat Res Ctr Aging Intervent, Busan 462414, South Korea
- Baek, Sang Hong교신저자Catholic Univ Korea, Div Cardiol, Dept Internal Med, 222 Banpo Daero, Seoul 137701, South Korea
- Park, Hun-Jun교신저자Catholic Univ Korea, Coll Med, Dept Med Life Sci, 222 Banpo Daero, Seoul 137701, South Korea
- 권상모교신저자Pusan Natl Univ, Med Res Inst, Sch Med, Dept Physiol,Lab Vasc Med & Stem Cell Biol, Yangsan 50612, South Korea
초록
Heart disease: keeping cardiac stem cells younger Stem cells for repairing damaged hearts could be kept in a younger and more viable state using a drug called MHY-1685 which assists processes that resist cell aging. Using stem cells to repair damaged heart tissue requires millions of cells but culturing a suitable cell type often causes many cells to age and become less viable. Ji Hye Park at Pusan University, Yangsan, South Korea, and colleagues explored the potential of MHY-1685 to rejuvenate human cardiac stem cells (hCSCs). The drug enhances a maintenance process called autophagy, which clears cells of worn-out components. Exposure to MHY-1685 generated stem cell populations that proved more effective than unexposed cells at repairing damaged heart tissue when transplanted into rats. Its potential for producing cells for treating patients should be explored. Stem cell-based therapies with clinical applications require millions of cells. Therefore, repeated subculture is essential for cellular expansion, which is often complicated by replicative senescence. Cellular senescence contributes to reduced stem cell regenerative potential as it inhibits stem cell proliferation and differentiation as well as the activation of the senescence-associated secretory phenotype (SASP). In this study, we employed MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, and examined its long-term priming effect on the activities of senile human cardiac stem cells (hCSCs) and the functional benefits of primed hCSCs after transplantation. In vitro experiments showed that the MHY-1685-primed hCSCs exhibited higher viability in response to oxidative stress and an enhanced proliferation potential compared to that of the unprimed senile hCSCs. Interestingly, priming MHY-1685 enhanced the expression of stemness-related markers in senile hCSCs and provided the differentiation potential of hCSCs into vascular lineages. In vivo experiment with echocardiography showed that transplantation of MHY-1685-primed hCSCs improved cardiac function than that of the unprimed senile hCSCs at 4 weeks post-MI. In addition, hearts transplanted with MHY-1685-primed hCSCs exhibited significantly lower cardiac fibrosis and higher capillary density than that of the unprimed senile hCSCs. In confocal fluorescence imaging, MHY-1685-primed hCSCs survived for longer durations than that of the unprimed senile hCSCs and had a higher potential to differentiate into endothelial cells (ECs) within the infarcted hearts. These findings suggest that MHY-1685 can rejuvenate senile hCSCs by modulating autophagy and that as a senescence inhibitor, MHY-1685 can provide opportunities to improve hCSC-based myocardial regeneration.
키워드
MYOCARDIAL-INFARCTIONPROGENITOR CELLSCARDIOMYOCYTESPROLIFERATIONRATSP53
식별자
- Scopus EID
- 2-s2.0-85115853225
- WoS UID
- 000701602900001
- KCI
- ART002756629



로그인
연구물 목록으로